The effect of local recurrence on survival in resected osteosarcoma

Weeden, Simon; Grimer, R. J.; Cannon, Stephen R.; Taminiau, A. H. M.; Uscinska, Barbara

doi:10.1016/s0959-8049(00)00362-2

Cited by 122 publications

(77 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 We have confirmed it's relationship to both margins of excision and to effectiveness of chemotherapy. If either of these are unsatisfactory then the risks of local recurrence increase.…”

Section: Discussionmentioning

confidence: 55%

Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres

Ford

Saithna

Grimer

et al. 2004

Sarcoma

View full text Add to dashboard Cite

Objective: To determine the prognostic value of patient and treatment parameters in osteosarcoma, and whether these are equally important across international boundaries. Design: Retrospective, cross-sectional study of 428 patients diagnosed with around-knee osteosarcoma, between 1990 and 1997 in Birmingham, UK, and Bologna, Italy. Disease-free survival (DFS) and overall survival (OS) assessed by KaplanMeier, Fisher's PLSD and Cox proportional hazard regression. Results: Five-year DFS and OS were 56 and 73% at Centre 1, compared to 43 and 60% at Centre 2 (P ¼ 0.0022 and P ¼ 0.025, respectively). The most important bad prognostic factors for DFS and OS respectively were raised alkaline phosphatase at diagnosis (P ¼ 0.002 and P ¼ 0.003), tumour necrosis < 90% following chemotherapy (P ¼ 0.001 and P ¼ 0.004) and volume >150 cm 3 at diagnosis (P ¼ 0.04 and P ¼ 0.006). The most significant combination of bad prognostic factors was alkaline phosphatase and tumour necrosis. A total of 73% of patients at Centre 1 had greater than 90% necrosis of the tumour following neoadjuvant chemotherapy compared with 29% at Centre 2. Conclusions: Tumour-based prognostic factors have similar significance across international boundaries. Chemotherapy effectiveness appears to be a major factor in explaining the survival difference between the two centres.

show abstract

Section: Discussionmentioning

confidence: 55%

Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres

Ford

Saithna

Grimer

et al. 2004

Sarcoma

View full text Add to dashboard Cite

show abstract

“…Local and metastatic relapses have been consistently demonstrated to markedly reduce survival (4,5). Although numerous studies have focused on improving the treatment of OS in order to enhance patient prognosis, early detection of cancer remains highly recommended for the improvement of survival rates (6).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma

Li¹,

Zhang²,

Liu³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are a family of small non-protein coding RNAs, which regulate the expression of a wide variety of genes at the post-transcriptional level to control numerous biological and pathological processes. Various circulating miRNAs have been identified as potential diagnostic and prognostic biomarkers in multiple types of cancer and disease. The aim of the present study was to identify potential miRNA biomarkers for the early diagnosis and relapse prediction of osteosarcoma (OS). miRNA profiling was performed on serum from patients with osteosarcoma and healthy controls. All putative miRNAs were verified by reverse transcription-quantitative polymerase chain reaction analysis of 20 pre-therapeutic OS patients and 20 healthy individuals. The expression of miR-106a-5p, miR16-5p, miR-20a-5p, miR-425-5p, miR451a, miR-25-3p and miR139-5p was demonstrated to be downregulated in the serum of OS patients when compared with that of the healthy controls. Receiver-operating characteristic curve analyses indicated that these 7 miRNAs may be used as diagnostic biomarkers with the ability to discriminate between the healthy cohort and patients with OS. These results provide novel insights into the use of miRNAs in early blood screening for OS.

show abstract

“…Limb-sparing surgery has become common as a result of better overall treatment [1,8,20,27]. However, local recurrence remains a significant problem, and this occurs in approximately 10% of patients treated with limbsparing surgery [3,4,7,11,19,21,23,29].…”

Section: Introductionmentioning

confidence: 99%

“…Some authors have reported on the clinical outcomes and prognostic factors of patients with locally recurrent osteosarcoma [4,6,10,12,19,23,28,29]. However, there are relatively little data on long-term clinical outcome and the results of different treatments.…”

Section: Introductionmentioning

confidence: 99%

What Are the Factors That Affect Survival and Relapse After Local Recurrence of Osteosarcoma?

Takeuchi

Lewis

Satcher

et al. 2014

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Despite improvements in treatment of primary osteosarcoma, treatment of patients who have local recurrence is not well defined. Questions/purposes We asked: (1) What are the 5-and 10-year overall survival rates of patients with osteosarcoma who have a local recurrence? (2) What factors are associated with better survival after a local recurrence? (3) Does chemotherapy affect overall survival after local recurrence? (4) What are the rates of rerecurrence after amputation and with limb salvage?Methods We reviewed 45 patients with nonmetastatic conventional high-grade osteosarcoma who had local recurrence between 1985 and 2007, during which time 461 patients were treated for the same disease. Seven patients with known local recurrence were lost to followup and not included in our study. The median age of the patients was 18 years, and minimum followup was 2 months (median, 39 months; range, 2-350 months). The primary tumor was located in the extremity in 36 patients and the pelvis in nine. The median time from initial surgery for resection or amputation of the primary tumor to local recurrence was 18 months (range, 2-149 months). Ten recurrences developed in bone and 35 in soft tissue. In 21 of the latter cases, the soft tissue recurrence was undetectable on conventional radiographs. Prognostic factors for overall patient survival after recurrence were evaluated by Kaplan-Meier survival and Cox multivariate analyses. Results Overall postrecurrence patient survival was 30% at 5 years and 13% at 10 years. Cox multivariate analysis revealed that concurrent metastasis (relative risk = 4, p = 0.003) and recurrent tumor size 5 cm or larger (relative risk = 13, p \ 0.0001) were independent predictors of worse survival. With the numbers available, treatment with chemotherapy after local recurrence was not associated with better survival (p = 0.54). Nine patients had a second local recurrence, and the actuarial risk of rerecurrence was 34% at 5 years. There was no difference in the frequency of rerecurrence between patients treated by amputation and wide local excision (p = 0.23).

show abstract

The effect of local recurrence on survival in resected osteosarcoma

Cited by 122 publications

References 17 publications

Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres

Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres

MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma

What Are the Factors That Affect Survival and Relapse After Local Recurrence of Osteosarcoma?

Contact Info

Product

Resources

About